B M Ravina

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. pmc Funding evidence: the National Institute of Neurological Disorders and Stroke Clinical Trials Program
    Bernard Ravina
    National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20892, USA
    NeuroRx 1:317-22. 2004
  2. pmc Donepezil for dementia in Parkinson's disease: a randomised, double blind, placebo controlled, crossover study
    B Ravina
    NINDS, Neuroscience Center Rm 2225, 6001 Executive Blvd, Rockville, MD 20892 9257, USA
    J Neurol Neurosurg Psychiatry 76:934-9. 2005
  3. ncbi request reprint The role of radiotracer imaging in Parkinson disease
    B Ravina
    National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA
    Neurology 64:208-15. 2005
  4. ncbi request reprint Neuroprotective agents for clinical trials in Parkinson's disease: a systematic assessment
    B M Ravina
    National Institute of Neurological Disorders and Stroke, National Institutes of Health, Rockville, MD 20892 9257, USA
    Neurology 60:1234-40. 2003
  5. ncbi request reprint SNCA multiplication is not a common cause of Parkinson disease or dementia with Lewy bodies
    J Johnson
    Laboratory of Neurogenetics, National Institute on Aging, NIH, Bethesda, MD 20892, USA
    Neurology 63:554-6. 2004
  6. ncbi request reprint Why hasn't neuroprotection worked in Parkinson's disease?
    Karl Kieburtz
    University of Rochester Medical Center, Rochester, NY, USA
    Nat Clin Pract Neurol 3:240-1. 2007
  7. ncbi request reprint Safety, tolerability, and pharmacokinetics of high-dose idebenone in patients with Friedreich ataxia
    Nicholas A Di Prospero
    Neurogenetics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892 3705, USA
    Arch Neurol 64:803-8. 2007
  8. ncbi request reprint Non-linearity of Parkinson's disease progression: implications for sample size calculations in clinical trials
    Paulo Guimaraes
    Dept of Biostatistics, Bioinformatics and Epidemiology, Medical University of South Carolina, 135 Cannon St Suite 303, Charleston, SC 29425, USA
    Clin Trials 2:509-18. 2005
  9. ncbi request reprint A randomized study of the bioavailability of different formulations of coenzyme Q(10) (ubiquinone)
    Radu Constantinescu
    Department of Neurology, Clinical Trials Coordination Center, University of Rochester Medical Center, Rochester, New York, USA
    J Clin Pharmacol 47:1580-6. 2007
  10. ncbi request reprint Randomized, placebo-controlled, parallel group versus crossover study designs for the study of dementia in Parkinson's disease
    Mary E Putt
    Department of Clinical Epidemiology and Biostatistics, School of Medicine, University of Pennsylvania, 621 Blockley Hall, 423 Guardian Drive, Philadelphia, PA 19104 6021, USA
    Control Clin Trials 23:111-26. 2002

Detail Information

Publications24

  1. pmc Funding evidence: the National Institute of Neurological Disorders and Stroke Clinical Trials Program
    Bernard Ravina
    National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20892, USA
    NeuroRx 1:317-22. 2004
    ....
  2. pmc Donepezil for dementia in Parkinson's disease: a randomised, double blind, placebo controlled, crossover study
    B Ravina
    NINDS, Neuroscience Center Rm 2225, 6001 Executive Blvd, Rockville, MD 20892 9257, USA
    J Neurol Neurosurg Psychiatry 76:934-9. 2005
    ..To study the safety and efficacy of a cholinesterase inhibitor, donepezil hydrochloride, for the treatment of dementia in Parkinson's disease (PD)...
  3. ncbi request reprint The role of radiotracer imaging in Parkinson disease
    B Ravina
    National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA
    Neurology 64:208-15. 2005
    ..Mechanistic information added by RTI to clinical trials may be difficult to interpret because of uncertainty about the interaction between the interventions and the tracer...
  4. ncbi request reprint Neuroprotective agents for clinical trials in Parkinson's disease: a systematic assessment
    B M Ravina
    National Institute of Neurological Disorders and Stroke, National Institutes of Health, Rockville, MD 20892 9257, USA
    Neurology 60:1234-40. 2003
    ..However, there have been relatively few clinical trials aimed at demonstrating neuroprotection. The authors sought to identify potential neuroprotective agents for testing in clinical trials...
  5. ncbi request reprint SNCA multiplication is not a common cause of Parkinson disease or dementia with Lewy bodies
    J Johnson
    Laboratory of Neurogenetics, National Institute on Aging, NIH, Bethesda, MD 20892, USA
    Neurology 63:554-6. 2004
    ..The authors did not identify any subjects with multiplication of SNCA and conclude this mutation is a rare cause of disease...
  6. ncbi request reprint Why hasn't neuroprotection worked in Parkinson's disease?
    Karl Kieburtz
    University of Rochester Medical Center, Rochester, NY, USA
    Nat Clin Pract Neurol 3:240-1. 2007
  7. ncbi request reprint Safety, tolerability, and pharmacokinetics of high-dose idebenone in patients with Friedreich ataxia
    Nicholas A Di Prospero
    Neurogenetics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892 3705, USA
    Arch Neurol 64:803-8. 2007
    ..Some studies suggest that higher doses of idebenone may be more effective, but pharmacology and toxicology at higher doses have not been investigated in human beings...
  8. ncbi request reprint Non-linearity of Parkinson's disease progression: implications for sample size calculations in clinical trials
    Paulo Guimaraes
    Dept of Biostatistics, Bioinformatics and Epidemiology, Medical University of South Carolina, 135 Cannon St Suite 303, Charleston, SC 29425, USA
    Clin Trials 2:509-18. 2005
    ..Models can help better understand behavior of the UPDRS after initiation of symptomatic therapy when scores will improve and eventually start deteriorating again...
  9. ncbi request reprint A randomized study of the bioavailability of different formulations of coenzyme Q(10) (ubiquinone)
    Radu Constantinescu
    Department of Neurology, Clinical Trials Coordination Center, University of Rochester Medical Center, Rochester, New York, USA
    J Clin Pharmacol 47:1580-6. 2007
  10. ncbi request reprint Randomized, placebo-controlled, parallel group versus crossover study designs for the study of dementia in Parkinson's disease
    Mary E Putt
    Department of Clinical Epidemiology and Biostatistics, School of Medicine, University of Pennsylvania, 621 Blockley Hall, 423 Guardian Drive, Philadelphia, PA 19104 6021, USA
    Control Clin Trials 23:111-26. 2002
    ..4 months, respectively, a substantial saving over either parallel group design. The cost of allowing for carryover in the sample size calculation is about 1.2 months of study time...
  11. ncbi request reprint Neuroprotection in Parkinson's disease: an elusive goal
    Kevin M Biglan
    Department of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, New York 14620, USA
    Semin Neurol 27:106-12. 2007
    ..Ultimately, overcoming the unique challenges of a heterogenous, slowly progressive disorder with multiple potential outcome measures will be necessary to identify treatments that have meaningful effects...
  12. ncbi request reprint A responsive outcome for Parkinson's disease neuroprotection futility studies
    Jordan J Elm
    Department of Biostatistics, Bioinformatics and Epidemiology, Medical University of South Carolina, Charleston, SC 29425, USA
    Ann Neurol 57:197-203. 2005
    ....
  13. ncbi request reprint Exercise-induced dystonia as a preceding symptom of familial Parkinson's disease
    Michiko K Bruno
    Parkinson s Unit, Division of Neurogenetics, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, USA
    Mov Disord 19:228-30. 2004
    ..Further genotype-phenotype studies in this and similar families may give clues to pre-symptomatic symptoms in PD and may reflect a particular phenotype of interest for genetics studies in the future...
  14. ncbi request reprint Brain banking for neurodegenerative diseases
    Diane D Murphy
    National Institute of Neurological Disorders and Stroke, NIH, MD 20852, USA
    Curr Opin Neurol 16:459-63. 2003
    ..The pathological substrates are then studied for their role in how they cause dysfunction in disease, or how their accumulation is presumably damaging...
  15. ncbi request reprint From chemical to drug: neurodegeneration drug screening and the ethics of clinical trials
    Jill Heemskerk
    Technology Development Program, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, Maryland 20892, USA
    Nat Neurosci 5:1027-9. 2002
  16. doi request reprint The Montreal cognitive assessment as a screening tool for cognitive impairment in Parkinson's disease
    David J Gill
    Department of Neurology, University of Rochester, Rochester, NY, USA
    Mov Disord 23:1043-6. 2008
    ..81. The correlation coefficient between the MoCA and a neuropsychologic battery was 0.72. The MoCA is reliable and valid in the PD population and warrants further study as a screening tool for cognitive dysfunction...
  17. ncbi request reprint Bilateral stimulation of the subthalamic nucleus in patients with Parkinson disease: a study of efficacy and safety
    Tanya Simuni
    Parkinson s Disease and Movement Disorders Center, Pennsylvania Hospital, Philadelphia, USA
    J Neurosurg 96:666-72. 2002
    ..The present study was designed to investigate the safety and efficacy of bilateral stimulation of the STN for the treatment of PD...
  18. ncbi request reprint Preference-based quality-of-life in patients with Parkinson's disease
    Andrew Siderowf
    Departments of Neurology, University of Pennsylvania School of Medicine, Philadelphia, USA
    Neurology 59:103-8. 2002
    ..Because of this property, they are the appropriate measures of quality of life for cost-effectiveness analysis. Although preference-based scales are widely used, their validity has rarely been tested in specific patient groups...
  19. ncbi request reprint Mutation at the SCA17 locus is not a common cause of parkinsonism
    Dena Hernandez
    Molecular Genetics Section, National Institute on Aging, National Institutes of Health, 9000 Rockville Pike, Bethesda, MD 20892, USA
    Parkinsonism Relat Disord 9:317-20. 2003
    ..We did not find any repeat sizes in the pathogenic range. The repeats we observed ranged from 29 to 41 (mean 36.8; median 37). We conclude that SCA-17 repeat expansion mutations are not a common cause of familial parkinsonism...
  20. ncbi request reprint Diagnostic criteria for psychosis in Parkinson's disease: report of an NINDS, NIMH work group
    Bernard Ravina
    Department of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, NY 14620, USA
    Mov Disord 22:1061-8. 2007
    ..These criteria require validation and may be refined, but form a starting point for studies of the epidemiology and pathophysiology of PDPsy, and are a potential indication for therapy development...
  21. pmc Widespread decrease of nicotinic acetylcholine receptors in Parkinson's disease
    Masahiro Fujita
    Molecular Imaging Branch, National Institute of Mental Health, National Institutes of Health, Building 1, Room B3 10, I Center Drive, MSC 0135, Bethesda, MD, USA
    Ann Neurol 59:174-7. 2006
    ..Nicotinic acetylcholine receptors have close interactions with the dopaminergic system and play critical roles in cognitive function. The purpose of this study was to compare these receptors between living PD patients and healthy subjects...
  22. ncbi request reprint Provisional diagnostic criteria for depression in Parkinson's disease: report of an NINDS/NIMH Work Group
    Laura Marsh
    Department of Psychiatry, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA
    Mov Disord 21:148-58. 2006
    ..The proposed diagnostic criteria are provisional and intended to be defined further and validated but provide a common starting point for clinical research in PD-associated depression...
  23. ncbi request reprint Early-onset Parkinson's disease caused by a compound heterozygous DJ-1 mutation
    Stephen Hague
    Molecular Genetics Section, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA
    Ann Neurol 54:271-4. 2003
    ..This subject was diagnosed with probable PD at age 24 years with asymmetric onset and an excellent response to levodopa therapy. Our observations suggest that sequence alterations in DJ-1 are a rare cause of early-onset PD...
  24. ncbi request reprint Neuroprotection in Parkinson's disease: myth or reality?
    Tiffini Voss
    Department of Neurology, University of Rochester School of Medicine and Dentistry, Movement and Inherited Neurological Disorders Unit, Rochester, NY 14620, USA
    Curr Neurol Neurosci Rep 8:304-9. 2008
    ..It is hoped that ongoing work in this field will lead to treatments that delay the progression of PD...